Below we present that DNL343 minimizes ISR activation and neurodegeneration brought on acutely by an optic nerve crush (ONC) injury or chronically by a germline eIF2B LOF mutation in mice. We also demonstrate that DNL343 treatment, initiated at a late phase of disease which more precisely replicates a scientific dosing https://titusrdpaj.idblogmaker.com/27860885/5-simple-statements-about-abbv-744-explained